Vannas, C.; Andersson, L.; Dolatabadi, S.; Ranji, P.; Lindén, M.; Jonasson, E.; Ståhlberg, A.; Fagman, H.; Åman, P.
Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines 2022, 10, 624.
https://doi.org/10.3390/biomedicines10030624
AMA Style
Vannas C, Andersson L, Dolatabadi S, Ranji P, Lindén M, Jonasson E, Ståhlberg A, Fagman H, Åman P.
Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines. 2022; 10(3):624.
https://doi.org/10.3390/biomedicines10030624
Chicago/Turabian Style
Vannas, Christoffer, Lisa Andersson, Soheila Dolatabadi, Parmida Ranji, Malin Lindén, Emma Jonasson, Anders Ståhlberg, Henrik Fagman, and Pierre Åman.
2022. "Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo" Biomedicines 10, no. 3: 624.
https://doi.org/10.3390/biomedicines10030624
APA Style
Vannas, C., Andersson, L., Dolatabadi, S., Ranji, P., Lindén, M., Jonasson, E., Ståhlberg, A., Fagman, H., & Åman, P.
(2022). Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines, 10(3), 624.
https://doi.org/10.3390/biomedicines10030624